Aspen Pharmacare HoldingsJSE:APN +0.66%73 EBITDA Margin % is 11.56% as of Dec. 2025, which is 51% below its 10-year median of 23.46. GuruFocus rates JSE:APN with a GF Score™ of 73/100 and a GF Value™ of R178.17 (Modestly Undervalued). The stock has 10 warning signs investors should review. Among 955 Drug Manufacturers companies, Aspen Pharmacare Holdings ranks worse than 73.82% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Aspen Pharmacare Holdings EBITDA Margin % Related Terms
Aspen Pharmacare Holdings EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JSE:APN vs ZTS, UTHR, VTRS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Aspen Pharmacare Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aspen Pharmacare Holdings EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aspen Pharmacare Holdings's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Aspen Pharmacare Holdings's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aspen Pharmacare Holdings (JSE:APN) has a EBITDA Margin % of 11.56% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Aspen Pharmacare Holdings and its competitors. This is 51% below median its historical median of 23.46. Over the past decade, Aspen Pharmacare Holdings' EBITDA Margin % has ranged from 1.54 to 27.49. According to the industry distribution chart, Aspen Pharmacare Holdings ranks #705 out of 955 companies in the Drug Manufacturers industry, placing it in the top 73.8%.
Is Aspen Pharmacare Holdings' EBITDA Margin % too high?
Aspen Pharmacare Holdings' current EBITDA Margin % of 11.56% is 51% below median its 10-year median of 23.46. Over the past 10 years, this metric has ranged from a low of 1.54 to a high of 27.49. The Drug Manufacturers industry median EBITDA Margin % is 12.44. Aspen Pharmacare Holdings' value of 11.56% is 7.1% below this industry median. Based on the distribution chart, Aspen Pharmacare Holdings ranks #705 out of 955 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Aspen Pharmacare Holdings has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aspen Pharmacare Holdings' EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Aspen Pharmacare Holdings ranks #705 out of 955 companies for EBITDA Margin %. This places Aspen Pharmacare Holdings in the lower half of its industry. The industry median EBITDA Margin % is 12.44. Aspen Pharmacare Holdings' value of 11.56% is 7.1% below this benchmark. Historically, Aspen Pharmacare Holdings' own EBITDA Margin % has ranged from 1.54 to 27.49 over the past decade. While the company's 10-year median is 23.46 vs. the industry median of 12.44, Aspen Pharmacare Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aspen Pharmacare Holdings's current EBITDA Margin % of 11.56% is 7.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Aspen Pharmacare Holdings and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aspen Pharmacare Holdings's current EBITDA Margin % is 11.56%, which is 51% below median its own 10-year median of 23.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aspen Pharmacare Holdings stock overvalued right now?
Based on GuruFocus' analysis, Aspen Pharmacare Holdings (JSE:APN) is currently considered Modestly Undervalued. The stock's GF Value™ is R178.17, compared to a current price of R154.85 — trading 13.1% below its estimated fair value. The current EBITDA Margin % is 11.56%, which is 51% below median its 10-year median of 23.46 and 7.1% below the Drug Manufacturers industry median of 12.44. Aspen Pharmacare Holdings' overall GF Score™ is 73/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Aspen Pharmacare Holdings (JSE:APN), the current EBITDA Margin % is 11.56% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aspen Pharmacare Holdings (JSE:APN) Overvalued in 2026?
Based on GuruFocus' analysis, Aspen Pharmacare Holdings stock appears to be undervalued.
The current stock price of R154.85 is trading 13.1% below its estimated GF Value™ of R178.17.
GuruFocus considers Aspen Pharmacare Holdings to be Modestly Undervalued.
Key valuation signals for JSE:APN:
EBITDA Margin %: 11.56% (51% below median its 10-year median of 23.46)
GF Value™: R178.17 vs. price of R154.85 (13.1% below fair value)
Industry Position: 7.1% below the Drug Manufacturers median (#705 of 955)
No single metric tells the full story. See the JSE:APN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aspen Pharmacare Holdings Ltd is a multinational pharmaceutical company. The group focuses on marketing and manufacturing a broad range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets. The business segments of the group are split between the Commercial Pharmaceuticals and Manufacturing segments. The Commercial Pharmaceuticals business segments are: Injectables, Over-the-counter, and Prescription. The Manufacturing business segments are: Active Pharmaceutical Ingredients, Finished Dose Form, and Heparin. Its geographic regions are Africa Middle East, Europe CIS, Australasia, Asia, and America.
73GF Score
Get the complete analysis for JSE:APN
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JSE:APN has been successfully added to your 
